Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.
The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out.
